Mandate

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB (publ) in connection with the acquisition of Ultinous Zrt., a Swedish-Hungarian AI inventor, for a consideration of SEK 45 million, on a cash and debt free basis and assuming normalized working capital, which will be paid through an issue in kind entailing 9,000,000 new shares in Irisity at a subscription price of SEK 5.00 per share. In conjunction with the Acquisition Stockhorn Capital AB (founded by Gustav Andersson and Inna Kaushan) will invest SEK 45 million in Irisity through a directed share issue on the same terms as in the In-kind Issue, i.e., SEK 5.00 per share. The transaction will be subject to national FDI Regulation requiring approval from Swedish and Hungarian authorities and Iristy's EGM resolving to authorize the board of directors to resolve on the share issues. As part of the acquisition and directed share issue, Irisity and Stockhorn Capital will also enter into a loan agreement pursuant to which Stockhorn Capital will lend Irisity an amount of SEK 15 million.

Vinge's team consists of Anders Strid, Edin Agic and Fredrik Löwenclou.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026